CAB-LA will be made at Indian drug company Cipla’s Benoni and Durban plants, but a starting date for production has not yet been announced
A generic version of a key cancer drug is now available in South Africa, but at a significantly higher cost than it is available internationally.
India’s pharmaceutical industry has rolled out a strong local presence in South Africa, cornering a large share of the market.